![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo](/content/dam/novonordisk/novomedlink/logos/bleeding-disorders/esperoct.svg)
aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.1 See Prescribing Information for complete product storage information.
Patients with hemophilia A said storage flexibility is the second strongest driver when choosing a product7,b
In a clinical study, the strongest drivers of product choice were origin of FVIII (plasma-derived vs recombinant), storage flexibility (temperature), reconstitution device7,b
bStudy of 200 patients diagnosed with moderate or severe hemophilia A to gain insights on usage of factor VIII products and to assess the impact and perceived importance of product storage. Data were collected via 30-minute, face-to-face interview and via a web-based survey. A questionnaire evaluated the effect of 6 features associated with factor VIII products on the choice of the product.7
Do you treat patients who are looking for flexibility that includes . . .
Ryan is 41 years old and has severe hemophilia A. He lives in a warm climate where the average monthly temperature is 95° F.
Actor portrayal. This is a hypothetical patient story.
Offer your patients like Ryan the broadest temperature stability1-6
Before reconstitution:
After reconstitution: use within 4 hours when stored at up to 86 °F or within 24 hours when stored in the refrigerator.1
See Prescribing Information for complete product storage information. Store reconstituted product in vial.
Current treatment experience
- SHL FVIII therapy 3x/week and an ABR of 5
- Has not expressed a strong interest in changing therapies
Daily life
- Active in local advocacy group
- Concerned about the long-term impact of bleeds
- Lives in an area prone to power outages and prefers to take his factor with him
ABR=annualized bleeding rate; FVIII=Factor VIII
Help your patients navigate coverage
NovoCare® offers cost savings and support programs for your eligible patients with bleeding disorders.
Order Esperoct® for your patients
Order Esperoct® by phone, through an authorized trading partner, or by contacting your local Novo Nordisk representative.
Selected Important Safety Information for Esperoct®
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
Indications and Usage
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes
- Esperoct® is not indicated for the treatment of von Willebrand disease
Important Safety Information
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
- Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
- Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®
Adverse Reactions
- The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.
Please click here for Esperoct® Prescribing Information.
- Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk, Inc.
- Adynovate® [package insert]. Lexington, MA: Baxalta US Inc; 2023.
- Afstyla® [package insert]. Kankakee, IL: CSL Behring LLC; 2023.
- Altuviiio® [package insert]. Waltham, MA: Bioverativ Therapeutics Inc; 2023.
- Eloctate® [package insert]. Waltham, MA: Bioverativ Therapeutics Inc; 2023.
- Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
- Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence. 2018;12:431-441.
- Giangrande P, Abdul Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost. 2020;18(suppl 10):5-14.
- Saulyte Trakymiené S, Economou M, Kenet G, Landorph A, Shen C, Kearney S. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: final results from pathfinder5. Thromb Haemost. 2020;18(suppl 10):15-25.
- Tiede A, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Chowdry P. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2022;28(1):27-35.
- Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117(9):1705-1713.
